Diagonal Bio AB strengthens its go-to-market strategy through an agreement with founding partner Johan Källstrand
Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") today announces a strategic step to strengthen its sales and marketing efforts. The company has secured the commitment of Johan Källstrand, one of the company's founders with extensive experience and knowledge within the company's market areas. The agreement means that Diagonal Bio is supported by Källstrand's long experience and deep knowledge to strengthen its go-to-market strategy.
Johan Källstrand, with a background and deep knowledge of Diagonal Bio's products, technologies, and market, will play a central role in the sales team and in the implementation of the go-to-market strategy and driving sales forward as well as strengthening Diagonal Bio's position on the market. Johan will be an integrated part of the sales team and work closely with management to implement strategies for maximizing sales of LAMPlify®. His role will include everything from customer engagement and market analyses to developing and implementing sales strategies that are tailored to Diagonal Bio's goals and ambitions.
The background that Källstrand possesses spans more than two decades, where he has taken leading roles within bio- and medtech, healthcare, and business development. Among his various commitments, his work as founder and COO of Parlametric AB since 2017, where he has played a critical role in the company's strategic and operational management, is notable. Källstrand's experience and work have not only strengthened operational capabilities but also highlighted his ability to drive innovation and market growth within technology-driven business development.
Källstrand's knowledge and merits within life science is an important resource for Diagonal Bio as the Company aims to expand its presence in the market and increase its sales pace. This partnership marks an exciting time for Diagonal Bio, with expectations that Johan Källstrand's contribution along with the management team will lead to significant progress in LAMPlify®'s sales strategies and market presence.
"We are enthusiastic to have Johan on board and his involvement is an important step to accelerate market presence. As Johan is one of our founding partners at Diagonal Bio, we believe that his deep understanding of our vision and products, specifically LAMPlify®, will be crucial in building strong customer relationships and driving sales” - Karin Wehlin, CEO Diagonal Bio AB (publ)
"Reconnecting with Diagonal Bio in this manner is both exciting and inspiring. I look forward to contributing to the company's success by leveraging my experiences and understanding of the industry. Together with the fantastic team at Diagonal Bio, I am confident that we can achieve new heights and deliver innovative solutions to customers" - Johan Källstrand, co-founder Diagonal Bio AB (publ)
For more information about the Company, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70 305 24 88
E-mail: kw@diagonalbio.com
www.diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.